ATE259878T1 - Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen - Google Patents

Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen

Info

Publication number
ATE259878T1
ATE259878T1 AT95939338T AT95939338T ATE259878T1 AT E259878 T1 ATE259878 T1 AT E259878T1 AT 95939338 T AT95939338 T AT 95939338T AT 95939338 T AT95939338 T AT 95939338T AT E259878 T1 ATE259878 T1 AT E259878T1
Authority
AT
Austria
Prior art keywords
hapten
immunogenicity
improving
immunogenic composition
producing vaccines
Prior art date
Application number
AT95939338T
Other languages
English (en)
Inventor
Hans Binz
Ngoc Thien Nguyen
Christine Andreoni
Per Ake Nygren
Stefan Stahl
Mathias Uhlen
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of ATE259878T1 publication Critical patent/ATE259878T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95939338T 1994-11-07 1995-11-07 Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen ATE259878T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413310A FR2726471B1 (fr) 1994-11-07 1994-11-07 Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
PCT/FR1995/001466 WO1996014416A1 (fr) 1994-11-07 1995-11-07 Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins

Publications (1)

Publication Number Publication Date
ATE259878T1 true ATE259878T1 (de) 2004-03-15

Family

ID=9468568

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939338T ATE259878T1 (de) 1994-11-07 1995-11-07 Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen

Country Status (15)

Country Link
US (2) US6149911A (de)
EP (1) EP0791064B1 (de)
JP (1) JPH10509311A (de)
AT (1) ATE259878T1 (de)
AU (1) AU712468B2 (de)
BR (1) BR1100315A (de)
CA (1) CA2204619A1 (de)
DE (1) DE69532588T2 (de)
DK (1) DK0791064T3 (de)
ES (1) ES2214511T3 (de)
FR (1) FR2726471B1 (de)
NZ (1) NZ296564A (de)
PT (1) PT791064E (de)
WO (1) WO1996014416A1 (de)
ZA (1) ZA959419B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
GB9920000D0 (en) * 1999-08-25 1999-10-27 Imp Cancer Res Tech Polypeptides
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
EP1174506A1 (de) * 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminales Erns-Peptide und Analoge davon
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US6970509B2 (en) * 2001-07-31 2005-11-29 Wis Technologies, Inc. Cell array and method of multiresolution motion estimation and compensation
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
FR2873378A1 (fr) * 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
US20080131450A1 (en) * 2004-07-23 2008-06-05 Pierre Fabre Medicament Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions
US8937153B2 (en) * 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
CA2799934C (en) 2010-07-07 2020-01-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods
EP2508537A1 (de) * 2011-04-04 2012-10-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quantitativer Standard für die Massenspektrometrie von Proteinen
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415491A (en) * 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
SE501169C2 (sv) * 1988-02-05 1994-11-28 Aake Nygren Framställning av serumalbuminbindande fusionsproteiner vilka innehåller protein G-domäner
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
EP0540645A4 (en) * 1990-07-24 1993-12-29 The Uab Research Foundation Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
SE9101433D0 (sv) * 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
GB9120221D0 (en) * 1991-09-23 1991-11-06 Smithkline Beecham Biolog Novel compounds
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins

Also Published As

Publication number Publication date
US6558673B1 (en) 2003-05-06
PT791064E (pt) 2004-07-30
US6149911A (en) 2000-11-21
DE69532588T2 (de) 2004-12-16
EP0791064B1 (de) 2004-02-18
DE69532588D1 (de) 2004-03-25
BR1100315A (pt) 1999-11-23
WO1996014416A1 (fr) 1996-05-17
NZ296564A (en) 1999-06-29
EP0791064A1 (de) 1997-08-27
ES2214511T3 (es) 2004-09-16
CA2204619A1 (fr) 1996-05-17
FR2726471B1 (fr) 1997-01-31
ZA959419B (en) 1996-05-28
DK0791064T3 (da) 2004-06-07
AU4120296A (en) 1996-05-31
AU712468B2 (en) 1999-11-04
JPH10509311A (ja) 1998-09-14
FR2726471A1 (fr) 1996-05-10

Similar Documents

Publication Publication Date Title
DE69532588D1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
ATE249840T1 (de) Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE265531T1 (de) Verfahren zur herstellung modifizierter immunoglobulinen mit reduzierter immunogenität der variablen domänen einer murinen antikörpers, zusammensetzungen die diese enthalten
DE2967697D1 (de) Rekombinante dns-molekuele und verfahren zur herstellung derselben.
ATE388162T1 (de) Verfahren zur beseitigung von viren
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE3788961D1 (de) Verfahren zur herstellung von polysubstituierten diethylentriaminpentaessigsäuren.
DE69132892D1 (de) Verfahren zur Herstellung von 4-Hydroxystyrol
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
DE3788229D1 (de) Verfahren zur isolierung von ca 125-antigen.
DE3584817D1 (de) Verfahren zur herstellung vom therapeutisch nutzbaren fviii/vwf-komplex und resultierende produkte.
DE3576952D1 (de) Verfahren zur herstellung von 4-phenyl-pyrrol-derivaten.
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DE3785157D1 (de) Verfahren zur herstellung von toxoid.
DE3667960D1 (de) Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung.
ATE121420T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)- l-thiazolidin-4-carbonsäure-derivaten.
DE3686811D1 (de) Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.
DE68904137D1 (de) Verfahren zur herstellung von 1,1,-dichlor-1-fluoroethan.
DE69133525D1 (de) Verfahren zur Herstellung von recombinantem Hepatitis B Oberflächenantigen mit erhöhter Immunogen-Kapazität und Verwendung in einer Impfstoffzubereitung
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
ATE187738T1 (de) Verfahren zur identifizierung und herstellung von bindungsstellen aufeinanderwirkender proteine
DE69101921D1 (de) Phosphortrilactame und verfahren zu deren herstellung.
DE69532533D1 (de) Verfahren zur herstellung von ranitidin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0791064

Country of ref document: EP

REN Ceased due to non-payment of the annual fee